Seeing the immune system in a newer, healthier light.

Our story began two decades ago with the groundbreaking work of our leading scientist and founder, Sudhir Agrawal. Through his pioneering research, first-, second-, and third-generation antisense chemistries were developed, and toll-like receptor (TLR) targeted compounds were discovered.

Now we’re setting out to create nucleic acid therapeutics that can control the immune response to be more targeted. We’re doing this through our two distinct technology platforms based on Dr. Agrawal’s pioneering nucleic acid science: TLR immune modulation and third-generation antisense.

  • Toll-Like Receptor Immune Modulation

    Through our TLR immune modulation platform, we’re designing drugs intended to turn the immune system off or on depending on the type of condition we are treating.